SELLAS Life Sciences (SLS) Stock Rockets 255% on Phase 3 Leukemia Trial Progress
SELLAS Life Sciences (SLS) stock rose 255% in 2025 as its Phase 3 REGAL trial for galinpepimut-S in acute myeloid leukemia met its 80-event benchmark. Recent research suggests standard therapies may underperform, potentially benefiting SELLAS. Institutional investors, including Quantinno Capital, increased stakes. Wall Street maintains a 'Hold' consensus with a $10.00 price target, below the current $15.46 share price.
How this was made
The 30-second read
Why it matters
The 80‑event benchmark achievement is a new, material fact that reduces trial uncertainty and may trigger significant price movement.
Market read
The news directly impacts SLS and could influence peer biotech stocks awaiting trial data.
What to watch
Potential dilution from future financing and the arbitration risk mentioned in the article.
Background
SELLAS Life Sciences (SLS) is a small‑cap biotech with no commercial revenue, relying on trial outcomes for valuation.
Ticker impact
SELLAS Life Sciences announced its Phase 3 REGAL trial reached the 80‑event benchmark, triggering final data analysis.
Potential upside of 30‑50% if final data exceed expectations; downside risk if data disappoint.
Biotech stocks react strongly to trial progress; the benchmark achievement is a fresh, material development.
Market effects
May lift sentiment across the leukemia‑focused biotech sector.
Limited to US biotech investors; no broader regional effect.
Modest global relevance, primarily for specialty pharma investors.
Counterpoint
If the final analysis shows marginal benefit, the stock could sharply reverse from its recent rally.
Key entities
- companySELLAS Life Sciences
Biotech developing galinpepimut‑S for acute myeloid leukemia.
- institutional_investorQuantinno Capital Management
New investor with a $315k stake in Q1.